Market closedADR
Amarin/AMRN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amarin
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Ticker
AMRN
Sector
Trading on
Industry
Biotechnology
Headquarters
Dublin, Ireland
Employees
-
Website
Amarin Metrics
BasicAdvanced
$236M
Market cap
-
P/E ratio
-$0.09
EPS
1.96
Beta
-
Dividend rate
Price and volume
Market cap
$236M
Beta
1.96
52-week high
$1.37
52-week low
$0.56
Average daily volume
722K
Financial strength
Current ratio
3.044
Quick ratio
1.867
Long term debt to equity
1.468
Total debt to equity
1.761
Interest coverage (TTM)
-3,347.63%
Management effectiveness
Return on assets (TTM)
-2.02%
Return on equity (TTM)
-5.98%
Valuation
Price to revenue (TTM)
0.889
Price to book
0.43
Price to tangible book (TTM)
0.44
Price to free cash flow (TTM)
-25.657
Growth
Revenue change (TTM)
-23.53%
Earnings per share change (TTM)
-4.81%
3-year revenue growth (CAGR)
-24.71%
3-year earnings per share growth (CAGR)
109.07%
What the Analysts think about Amarin
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Amarin stock.
Amarin Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Amarin Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Amarin News
AllArticlesVideos
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
GlobeNewsWire·2 months ago
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
GlobeNewsWire·2 months ago
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Amarin stock?
Amarin (AMRN) has a market cap of $236M as of October 26, 2024.
What is the P/E ratio for Amarin stock?
The price to earnings (P/E) ratio for Amarin (AMRN) stock is 0 as of October 26, 2024.
Does Amarin stock pay dividends?
No, Amarin (AMRN) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next Amarin dividend payment date?
Amarin (AMRN) stock does not pay dividends to its shareholders.
What is the beta indicator for Amarin?
Amarin (AMRN) has a beta rating of 1.96. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.